Engineers at Rice University have 1 a smart implant that can deliver precise doses of medication for years without requiring refills or replacement. The device could transform treatment of chronic conditions and potentially enable new longevity interventions requiring long-term drug delivery.
The implant, 1 in Science Robotics, uses a novel microfluidic system powered by the body own electrical signals, eliminating the need for batteries and creating a device that can function indefinitely.
The Drug Delivery Challenge
Many promising therapies fail not because they do not work, but because patients cannot or will not take them consistently. Adherence to medication regimens hovers around 50% for chronic conditions—a major factor in treatment failure. For longevity interventions, the challenge is amplified. Drugs like rapamycin may need to be taken for decades. Senolytic cocktails require periodic dosing at specific intervals. Growth factors often cannot survive oral delivery.
How the Device Works
The Rice implant contains hundreds of tiny microreservoirs containing drug payload, electroactive valves that open in response to electrical signals, a biofuel cell that harvests electricity from glucose in interstitial fluid, a wireless receiver accepting commands from an external controller, and biocompatible titanium and polymer housing that integrates with tissue. The device can be implanted subcutaneously in a simple outpatient procedure and programmed wirelessly to release precise drug doses on customizable schedules.
Key Specifications
The device measures approximately the size of a grain of rice (3mm x 10mm) and can hold up to 5 years of drug supply depending on dose requirements. Dosing is precise to the nanoliter with timing control to seconds. Power is self-sustaining through the biofuel cell with no battery replacement needed, and later versions will allow transcutaneous refilling.
Potential Applications
The researchers envision uses including automated insulin delivery for diabetes, precise local drug delivery for pain management, sustained release of chemotherapy directly to tumors, and timed release of senolytics, rapamycin, or future aging interventions. For hormone replacement, it could provide physiologic dosing patterns impossible with pills.
Longevity-Specific Potential
Several longevity interventions could benefit: rapamycin optimal dosing may require intermittent pulsing easily programmable in an implant; senolytic protocols often call for periodic dosing that patients forget; proteins like Klotho could be delivered locally; and repeat dosing of AAV gene therapy vectors could be timed carefully.
Regulatory and Commercial Path
The Rice team has formed a startup, NeuroSync Medical, to commercialize the technology. Initial FDA submissions will focus on pain management and diabetes—established medical needs with clearer regulatory pathways. Longevity applications face the additional challenge of aging not yet being recognized as an indication by most regulators.
